Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.36 |
| ▸ | MME | P08473 | 7/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364020 | 0.84 | MME (0.36) | MAOBROCK2MMEFFAR4ROCK1 | |
| SCHEMBL24380861 | 0.84 | MME (0.36) | MAOBROCK2MMEFFAR4ROCK1 | |
| SCHEMBL24428847 | 0.84 | ROCK2 (0.39) | MAOBROCK2MMEFFAR4HTR2A | |
| SCHEMBL16979073 | 0.78 | CHRM1 (0.37) | MAOBROCK2FFAR4HTR2AHTR2C | |
| SCHEMBL16979069 | 0.76 | KCNA5 (0.43) | MAOBROCK2 | |
| SCHEMBL16939702 | 0.75 | ROCK2 (0.34) | MAOBROCK2MMEFFAR4PIM1 | |
| SCHEMBL24380930 | 0.75 | ROCK2 (0.34) | MAOBROCK2MMEFFAR4PIM1 | |
| SCHEMBL24381002 | 0.73 | MME (0.34) | MMEFFAR4PIM1PIM2 | |
| SCHEMBL18595125 | 0.73 | MME (0.34) | MMEFFAR4PIM1PIM2 | |
| SCHEMBL16974261 | 0.71 | FFAR4 (0.36) | ROCK2MMEFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MAOB 62/4885ROCK2 1055/4885MME 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.